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ABSTRACT The World Health Organization (WHO) has announced that Severe Acute Respiratory Syndrome Coronavirus‐2
(SARS‐CoV‐2) and Coronavirus disease (COVID‐19) is considered a worldwide pandemic. Rapidly rising numbers of patients
have been reported in almost every country, along with the growing mortality rates. Uncontrolled growth in patient numbers
may be due to reasons such as treatment options and vaccine availabilities and unidentified targets of SARS‐CoV‐2. Previous
study has revealed that the molecular target of SARS‐CoV‐2 is analogous to SARS (2003), i.e. angiotensin‐converting
enzyme‐2 (ACE‐2). Therefore, the determination of ACE‐2 may enrich existing information and facilitate development
of drugs targeted toward SARS‐CoV‐2. This study aims to screen the expression of ACE‐2 genes and their relationship
to the types of SNP variants in SARS‐CoV‐2. We explored a series of observations using powerful databases, e.g. GTEx
portal, HaploReg, 1000 Genome and Ensembl, to identify the gene variant of ACE‐2. We showed that ACE‐2 is highly
expressed in the testes and small intestine, while its lowest level is observed in lymphocytes. Subsequently, we observed
17 gene variants containing a missense mutation potentially damaging protein level. Among these genes, single nucleotide
polymorphism (SNP) rs370187012 shows the highest damage‐level score, while the lowest effect is in SNP rs4646116.
The highest frequency of the C allele was observed in European populations (1%). In addition to showing that ACE‐2 is
expressed in several organs, we concluded that the ACE‐2 gene variation can be found in African, American, Southeast and
East Asian, and European populations. The polymorphisms of ACE‐2 impact on the ACE2 protein structure and the binding
capacity of the ACE‐2 receptor with the S‐Protein of SARS‐CoV‐2.
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1. Introduction
Continuous increment of patients suffering from SARS­
CoV­2 infection across continents, i.e., Asia Pacific, Eu­
rope, America, and Africa, has threatened humans glob­
ally. Enforced by an uncontrolled number of SARS­CoV­
2 patients, WHO as per­11 March 2020 announced that
the status of global SARS­CoV­2 had reached an outbreak
pandemic. According to an update from Worldometers
(Worldometer 2020a) as per­17 January 2021: 94,949,414
confirmed cases; 2,030.914 deaths; and 67,773,034 cured
patients COVID­19 were reported among 215 countries,
since the first case allegedly reported in Wuhan, Hubei,
China in December 2019. Each country has conducted
various strategies to uplift the prevention of the disease,
mainly by restraining the air flights towards pandemic
sides and vice versa.
This coronavirus is firstly known as “2019 novel
coronavirus”. Furthermore, it was officially changed
to “COVID­19” and included the type of SARS­CoV­2
virus. The SARS­CoV­2 is regarded as the cause, while
COVID­19 is referring to the disease caused by SARS­
CoV­2. Providing the disease name is the authority of
WHO through standardized International Classification of
Disease (ICD). The International Committee on Taxon­
omy of Viruses (ICTV) of WHO legitimately announced
the rise of SARS­CoV­2 on 11 February 2020, consider­
ing the virus is genetically analogous to the type of SARS
coronavirus spread in 2003.
Given the current surge of cases that occur mainly in
the Asian population, scientists put the suspect on them
and further observe the factors. One may provide the in­
sight answer to the question is the genetics/genomic sci­
ence. Genetics science studied the overall information
about the genetic who owned a cell or organism, while the
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genome is a plural form of genetics. Thus far, scientists are
trying their best to cope with the SARS­CoV­2, i.e. iden­
tify the origin of the virus through sequencing/mapping of
SARS­CoV­2 and compare with some animals considered
or suspected as the virus origin as bat found in the tradi­
tional market in Wuhan.
Scientists have been identifying various possibilities
of genes damaged by the virus. Instead, one was also at­
tempting to identify the receptor of SARS­CoV­2 itself.
Chao and co­workers analyzed the comparison of human
gene characteristics in several populations and correlated
it with their vulnerability against COVID­19 (Cao et al.
2020). They elucidated the angiotensin­converting­2 en­
zyme (ACE­2) as one of the receptors of SARS­CoV­2.
ACE­2 receptors are generally found in the respiratory
tract. Some previous studies reported reinforcing the hy­
pothesis that ACE­2 is strongly evident as the receptor or
supreme target of SARS­Cov­2 (Zhou et al. 2020; Lu et al.
2020).
Additionally, an in­vitro study also represented the
positive correlations between the ACE­2 expression with
SARS­CoV in 2003 (Hofmann et al. 2004; Li et al. 2007).
The SARS­Cov­2 enables binding ACE­2 with a strong
affinity towards S­protein (Li et al. 2005). There is an ur­
gent necessity to screen the expression of ACE­2 genes
and their relation to SNP variants types in SARS­CoV­2.
Previous studies have not explored the types of variations
in the ACE­2 gene, which are susceptible to SARS­CoV­2
and especially to the outbreak pandemic. Regarding the
fundamental role of ACE2 in SARS­CoV­2 cell entry, and
as a potential therapeutic target for antiviral therapy, in this
study, we used several databases to investigate related ex­
pression profiles and SNPs of ACE2. Using the various
databases, we found that the results were consistent with
some previous studies (Hikmet et al. 2020; Paniri et al.
2021) that ACE­2 expressed in several organs, including
the respiratory tract. The polymorphisms ofACE­2 impact
the ACE2 protein structure, function and this also affected
to ACE2 ­dependent cell entry of SARS­CoV­2. This in­
formation will be beneficial for further research in regards
to SARS­CoV­2.
2. Materials and Methods
In order to find the expression of ACE ­2 genes, the GTEx
portal database (GTExPortal 2020), a site that contains all
genes expression, was used to identify the types of SNPs
in the ACE ­2 gene. The GTEx portal database was re­
trieved on 20 June 2020. Afterward, to confirm the type of
mutated genes that affect the level of protein or so­called
the gene coding protein (variation type of genes of mis­
sense mutase), we then use Haploreg version 4.1 (Hap­
loReg 2020) and 1000 Genome project (AsiaEnsemble
2020). Upon identifying the types of non­synonym SNPs
or missense mutase, we employ the Ensembl database to
compare the SNP among the worldwide population. En­
sembl encompasses a database that more specifically pre­
dicts protein changes, i.e. PolyPhen­2. This database di­
vided the changes of protein into three categories based
on score and level of SNP damage in protein: score 0.00
­ 0:15 (benign), 0.15 ­ 0.85 (possibly damaging), and 0.85
­ 1.00 (probably damaging), with the range between 0 to
1. This study investigated several affected populations
by SARS­Cov­2, including Europe, Southeast and South
Asia, America, and Africa.
3. Results and Discussion
3.1. Identification of ACE‐2 gene expression over vari‐
ous organs
The well­known database used to contain all gene expres­
sions of human organs is expression quantitative trait loci
(eQTLs), which is loaded on the GTEx database (Ardlie
et al. 2015). By comparing them with accessible genome
databases such as the 1000 Genome database, the out­
come allows us to identify the types of genes in a cer­
tain population, i.e., Asia, when most SARS­CoV­2 out­
breaks occurred. Using a website database (GTExPortal
2020), results showed that ACE­2 genes positively asso­
ciate with ACE­2 expression in several organs. (Figure
1.). Figure 1 shows the expression of ACE­2 in several
organs, which were scoring with log10 (Transcripts Per
Million (TPM) +1). ACE­2 was highly expressed in the
testis (median TPM in male was 46.53), small intestine or
the terminal ileum (median TPM in female 50,06; male
24.45), adipose visceral (median TPM in female 9.409;
male 8.543), kidney (median TPM in female 10.70; male
7.676), heart ­ left ventricle (median TPM in female 8.991;
male 6.896), thyroid (median TPM in female 6.172; male
6.414), heart ­ atrial appendage (median TPM in female
5.706; male 5.422), colon – transverse (median TPM in fe­
male 4.679; male 2.775), while the lowest level observed
in lymphocytes (median TPM in female 0.02405; male
0.01637). We also identified that ACE­2 was expressed
in the human lung (median TPM in females 0.94; male
1.044), which this organ knew as the host for SARS­CoV­
2. It is also confirmed that the ACE­2 gene tended to
be expressed in the female gender (cervix ­ ectocervix,
cervix ­ endocervix, uterus, fallopian tube, ovary, and
vagina) compared to the male (testis, kidney ­ medulla and
prostate). However, sequencing/ RNA mapping showed
that the male Asian population showed a higher ACE­2
gene expression than the female (Zhao et al. 2020). This
finding is in accordance with the data reported by Worl­
dometers (Worldometer 2020b), indicates that the death
rate of male patients is merely higher (61.8%) than that
of female (38.2%).
3.2. Identification of ACE‐2 gene variation affecting
the protein change
Single nucleotide polymorphisms (SNPs) are able to im­
pact protein function, structure, stability, and abundance
(Calcagnile et al. 2020). For identifying the gene varia­
tion affecting the protein change, we used Haploreg ver.
4.1 and 1000 genome project databases that contain 2.6
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million gene variations of SNPs (Devuyst 2015). We ob­
serve 128 SNPs that have a variety of missense mutations.
Through further Ensembl database, we identified 17 SNPs
that may impact the protein alteration types with the fol­
lowing types: probably damaging, possibly damaging, and
hyperplasia (Table 1). We further identified that 17 gene
variations of ACE­2 have an alleles variety of <1% over
the population of African, American, and Asian. This
data indicates that the ACE­2 is rarely observed in those
populations. However, for SNP rs4646116, the allele fre­
quency of European showed over 1%. This study also
demonstrated that the ACE­2 gene with SNP rs370187012
is the most potent contributing to protein levels alter­
ation through a predicted probably damaging. Ensembl
database observation also indicates the rs370187012 allele
frequency of <0.1% among the Southeast Asian popula­
tion in which is one of the most affected regions of SARS­
CoV­2 and COVID­19 outbreak (Table 1).
3.3. Discussion
Increase evidence of COVID­19 has been a massive threat
around the world. Scientists are still searching for a break­
through to overcome the SARS­CoV­2 attack by identi­
fying the causes and biological receptors targeted by this
virus. For instance, as the SARS receptor has been iden­
tified (ACE­2) in 2003 (Hofmann et al. 2004), the ini­
tial step to encounter the new virus can be probably ini­
tiated by using the similar target receptor to correlate with
the binding to the new virus (Zhang et al. 2020). In this
study, we used a gene expression database to identify the
ACE­2 most­expressing organs. Several previous studies
have been conducted andmentioned that ACE­2 is utmost­
expressed in the respiratory system, thus may become one
of the possible pathways to cure COVID­19 (Zhang et al.
2020). However, from our data, we found that the expres­
sion of ACE­2 in the respiratory system was not very high
(Figure 1). The higher expression of ACE2 may be due
to comorbidity, including hypertension, coronary artery
disease, chronic obstructive pulmonary disease, diabetes
mellitus, chronic kidney disease, obesity and smoking pa­
tients (Guan et al. 2020). Furthermore, changes in the ex­
pression levels of ACE2 correlate with SNPs, splicing, and
transcription processing which could raise the vulnerabil­
ity of individuals to COVID­19 infection. We further as­
TABLE 1 Distribution of allele frequencies of ACE‐2 along with the impact for proteins.










Allele Africa America EAS SAS EUR
rs370187012 chrX ACE2 R710H 0.999 ProbablyDamaging C T 0 0 0.000163 0 0
rs776995986 chrX ACE2 R708W 0.997 ProbablyDamaging G A 0 0 0 0 0
rs758142853 chrX ACE2 V184A 0.996 ProbablyDamaging T C 0 0 0 0 0
rs140016715 chrX ACE2 R768W 0.995 ProbablyDamaging G A 0.000081 0 0.000085 0 0
rs147311723 chrX ACE2 L731F 0.941 ProbablyDamaging G A 0.014754 0.000496 0 0
rs754511501 chrX ACE2 G173S 0.876 PossiblyDamaging A G 0 0 0 0 0
rs373153165 chrX ACE2 D785N 0.838 PossiblyDamaging T C 0 0 0 0 0
rs191860450 chrX ACE2 I468V 0.747 PossiblyDamaging G A 0 0 0 0 0
rs73635825 chrX ACE2 S19P 0.74 PossiblyDamaging A G 0.003423 0 0 0 0
rs149039346 chrX ACE2 S692P 0.723 PossiblyDamaging A G 0.004946 0.000037 0 0.000053 0
rs748163894 chrX ACE2 A627V 0.713 PossiblyDamaging T C 0 0 0 0 0
rs140473595 chrX ACE2 A501T 0.323 Benign G A 0 0 0 0 0
rs183135788 chrX ACE2 N638S 0.054 Benign T C 0 0 0 0 0
rs41303171 chrX ACE2 N720D 0.02 Benign T C 0.003053 0.002695 0 0.00434 0
rs373252182 chrX ACE2 N149S 0.015 Benign T C 0 0 0 0 0
rs200180615 chrX ACE2 E668K 0.005 Benign C T 0 0 0 0 0
rs4646116 chrX ACE2 K26R 0.001 Benign T C 0.000988 0.003286 0.000072 0.001313 0.01
EAS: East Asia; SAS: Southeast Asia; EUR: Europe
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FIGURE 1 Gene expression of ACE‐2 in several organs (The (GTExPortal 2020)
FIGURE 2 Distribution of allele frequencies of ACE‐2 type‐SNP rs4646116 type in some populations. Abbreviations: AMR; America, AFR;
Africa, EUR: Europe, EAS; East Asia, SAS; Southeast Asia.
sessed the correlation of population with COVID­19 with
the gene variant. A study conducted by Chao and co­
workers showed that SNP with rs4646127 located in in­
tron ACE­2 is the highest frequency of an allele in China
population 0.997 and Southeast Asia (0.994) (Cao et al.
2020). Compared to Europe and the US data, the SNP of
rs4646127 showed much lower expression of an allele in
China, 0.651 and 0.754, respectively. Nevertheless, this
SNP type suggests an intone, which is not a coding type of
protein that can trigger a change in protein level.
In this study, we employed several gene variety
databases, 1000 genome database, and GTEx database that
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may enhance the SNP signal present and potentially de­
tected the phenotype changes possibility or, in this case,
correlated highly to COVID­19. The presence of SNPs
within the coding region of ACE­2 can result in the alter­
ation of amino acid sequence. This change in amino acid
sequence at the interaction site can affect the binding ca­
pacity of the ACE­2 receptor with the S­Protein of SARS­
CoV­2. Furthermore, SNPs within promoter or 3′­UTR
can cause downregulation of the ACE­2 gene resulting in
lower levels of ACE­2 receptor at the cell surface for inter­
actionwith virus particles (Chaudhary 2020). We found 17
types of ACE­2 variation, which are the potential to give
impact down to the protein level. This fact may help raise
clues to assess the COVID­19 severity in correlation with
the ACE­2 gene and its coexistence with diseases, such
as pneumonia. The SNP rs370187012 with 0.999 scores
showed potential damage for R710H protein type, while
SNP rs4646116 showed the lowest score of 0.001 along
with benign potency, or rarely inducing any protein mu­
tation. However, further responsible steps are required
to ensure the vulnerability of the ACE­2 gene of SARS­
CoV2 infected patients toward the COVID­19. Further­
more, a noteworthy fact is underlined herein, that SNP
rs4646116 appears among Europe population with more
than 1% occurrence probability of the ACE­2; meanwhile,
the other populations, viz. The US and Asia show lower
probability frequency (less than 1%). The rs4646116
(K26R), rs149039346 (S692P), and rs41303171 (N720D)
located in the helix, helix and coil structure, respectively.
Phyre2 software indicated that S692P protein changing
probably causes disorder with relatively high confidence.
Change in ACE2 structure affected COVID­19 cell entry,
and therefore its replication in host cells, especially lung
(Liu et al. 2020; Sommerstein et al. 2020). The polymor­
phisms of ACE­2 impact the ACE2 protein structure, af­
fecting the binding capacity of the ACE­2 receptor with
the S­Protein of SARS­CoV­2.
Overall, our data is fairly restricted to early identifica­
tion of gene variation of ACE­2 using the databases study
and prioritizing the gene variety of mutated type, mis­
sense. Further validation of such experiments associated
with SNP types among­ and inter­populations of COVID­
19 patients are highly required to verify the allele differ­
ence among the different populations of COVID­19. Thus,
it may provide more data in regards to ACE­2 gene vulner­
ability for various SNPs of the COVID­19 patients.
4. Conclusions
A vigorous database search has successfully provided an
insight into ACE­2 gene variation and evidence of ACE­
2 expressed in the testis, small intestine or the termi­
nal ileum, adipose visceral, kidney heart ­ left ventricle,
thyroid, heart ­ atrial appendage, colon ­ transverse and
the respiratory tract, which has been well­known as the
SARS­CoV­2 target. Furthermore, we identified 17 vari­
ants of SNPs missense mutation that play a potential role
in protein changes, along with SNP rs370187012 and SNP
rs4646116 regarded as the highest and lowest protein al­
terations, respectively.
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